Combination raltitrexed (Tomudex®)-oxaliplatin: A step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

European Journal of Cancer

Volumn 36, Issue 12, 2000, Pages 1514-1521

  Fizazi, K ^a   Caliandro, R ^a   Soulie P ^a   Fandi, A ^a   Daniel, C ^a   Bedin, A ^a   Doubre, H ^a   Viala, J ^a   Rodier, J M ^a   Trandafir, L ^a   Le Chevalier, T ^a   Cvitkovic, E ^a   Armand, J P ^a   Ruffie P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Immunotherapy; Mesothelioma; Oxaliplatin; Raltitrexed

Indexed keywords

ALPHA INTERFERON; CISPLATIN; INTERLEUKIN 2; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; RALTITREXED; SEROTONIN 3 ANTAGONIST;

ARTICLE; ASTHENIA; CANCER REGRESSION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MESOTHELIOMA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MESOTHELIOMA; MIDDLE AGED; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; THIOPHENES;

EID: 0033853919     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00139-8     Document Type: Article

References (62)

1. Alberts A., Falkson G., Goedhals L., Vorobiof D., Van der Merwe C. Malignant pleural mesothelioma. a disease unaffected by current therapeutic maneuvers J. Clin. Oncol. 6:1988;527-535.
2. Ruffie P., Feld R., Minkin S.et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec. a retrospective study of 332 patients J. Clin. Oncol. 7:1989;1157-1168.
3. Rusch VW and the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995, 108, 1122-1128.
4. Peto J., Hodgson J.T., Matthews F.E., Jones J.R. Continuing increase in mesothelioma mortality in Britain. Lancet. 345:1995;535-539.
5. Boutin C., Rey F., Viallat J.R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 108:1995;754-758.
6. Chahinian AP, Rusch VW. Malignant mesothelioma. In Holland JF, et al., eds. Cancer Medicine, 4th edn. Baltimore, Williams and Wilkins, 1997, 1805-1826.
7. Ong S.T., Vogelzang N.J. Chemotherapy in malignant pleural mesothelioma. A review. J. Clin. Oncol. 14:1996;1007-1017.
8. Ryan C.W., Herndon J., Vogelzang N.J. A review of chemotherapy trials for malignant mesothelioma. Chest. 113:1998;66S-73S.
9. Baas P., Scouwink H., Zoetmulder F.A.N. Malignant pleural mesothelioma. Ann. Oncol. 9:1998;139-149.
10. Soulié P., Ruffié P., Trandafir L.et al. Combined systemic chemoimmunotherapy in advanced diffuse mesothelioma. report of a phase I-II study of weekly cisplatin/interferon alfa-2a J. Clin. Oncol. 14:1996;878-885.
11. Trandafir L., Ruffié P., Borel C.et al. Higher doses of α-interferon do not increase the activity of the cisplatin-interferon combination in advanced malignant mesothelioma. Eur. J. Cancer. 33:1997;1900-1902.
12. Rodier J.M., Couteau C., Ruffie P.et al. Phase II study of a monthly combination of cisplatin, mitomycin C and interferon alfa in malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 15:1996;390.
13. Caliandro R., Escudier B., Grall I.et al. Etude de phase II de chimio-immunothérapie séquentielle de l'association cisplatine (CDDP) IV, interleukine 2 (IL2) sous-cutanée, α-interferon (IFN) dans le mésothéliome malin diffus de la plèvre (MMDP). Bull. Cancer. 85:1998;495.
14. Caliandro R., Boutin C., Perol M.et al. Phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in advanced pleural malignant mesothelioma (MM). Lung Cancer. 18(Suppl. 1):1997;19.
15. Fizazi K., Ducreux M., Ruffié P.et al. A phase I, dose-finding and pharmacokinetic study of raltitrexed ('Tomudex') combined with oxaliplatin in patients with advanced cancer. J. Clin. Oncol. 18:2000;2293-2300.
16. Fizazi K., Viala J., Daniel C.et al. Raltitrexed ("Tomudex") and oxaliplatin. an active out-patient regimen in malignant mesothelioma Eur. J. Cancer. 35(Suppl. 4):1999;S252.
17. Berghmans T., Paesmans M., Lalami Y.et al. Chemotherapy for malignant mesothelioma. a quantitative and qualitative overview of the literature Proc. Am. Soc. Clin. Oncol. 18:1999;481a.
18. Levin L., Simon R., Hryniuk W.et al. Importance of mutiagent chemotherapy regimens in ovarian carcinoma. dose intensity analysis J. Natl. Cancer Inst. 27:1991;1367-1372.
19. Fizazi K., Zelek L. "One cycle every 3 or 4 weeks": is it obsolete? A review of dose-dense chemotherapy in solid neoplasms. Ann. Oncol. 11:2000;133-149.
20. Rebattu P., Merrouche Y., Blay J.Y.et al. Phase II study of very high dose cisplatin (CDDP) in mesothelioma. Eur. Respir. Rev. 3:1993;226-228.
21. Planting A.S.T., Schellens J.H.M., Goey S.H.et al. Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann. Oncol. 5:1994;373-374.
22. Sklarin N.T., Chahinian P., Fever E.et al. Augmentation of activity of cisplatinum and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res. 48:1988;64-67.
23. Chahinian A.P., Antman K., Goutsou M.et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J. Clin. Oncol. 11:1993;1559-1565.
24. Eggermont A.M.M., Goey S.H., Slingerland R.et al. Clinical and immunological evaluation of intrapleural interleukin 2 in malignant pleural mesothelioma. A phase I-II study. Proc. Am. Assoc. Cancer Res. 32:1991;206.
25. Khayat D., Borel C., Tourani J.M.et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alpha-2a for metastatic melanoma. J. Clin. Oncol. 11:1993;2173-2180.
26. Escudier B., Theodore C., Fizazi K.et al. Treatment of metastatic renal cell carcinoma with interferon and interleukin 2. a new efficient outpatient regimen Proc. Am. Soc. Clin. Oncol. 17:1998;330a.
27. Chahinian A.P., Gluck H., Teirstein A.S. Effectiveness of suramin, taxol and cisplatin alone and in combination against human malignant mesothelioma xenografts. Proc. Am. Assoc. Cancer Res. 36:1995;1807.
28. Lee J.M., Bruckner H.W., Szrajer L.et al. Taxol inhibits growth of mesothelioma xenografts. Anticancer Res. 15:1995;693-696.
29. Vogelzang N.J., Herndon J., Clamon G.H.et al. Paclitaxel (Taxol) for malignant mesothelioma (MM). a phase II study of the Cancer and Leukemia Group B (CALGB 9234) Proc. Am. Soc. Clin. Oncol. 13:1994;405.
30. Belli L., Le Chevalier T., Gottfried M.et al. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer. Preliminary results. Semin. Oncol. 22(Suppl. 15):1995;29-33.
31. Rothenberg M.L., Moore M.J., Cripps M.C.et al. A phase II trial of gemcitabine in patients with 5FU-refractory pancreas cancer. Ann. Oncol. 7:1996;347-353.
32. Fitzpatrick D.R., Manning L.S., Musk A.W.et al. Potential for cytokine therapy of malignant mesothelioma. Cancer Treat Rev. 21:1995;273-288.
33. Von Hoff D.D., Huong A.M. Effect of recombinant interferon-beta ser on primary human tumor colony-forming units. J. Interferon Res. 8:1988;813-820.
34. Christmas T.I., Manning L.S., Garlepp M.J.et al. Effect of interferon-alpha 2a on malignant mesothelioma. J. Interferon Res. 13:1993;9-12.
35. Ardizzoni A., Pennucci M.C., Castagneto B.et al. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am. J. Clin. Oncol. 17:1994;80-82.
36. Von Hoff D.D., Metch B., Lucus J.G.et al. Phase II evaluation of recombinant interferon-beta (FN-beta ser) in patients with diffuse mesothelioma. a Southwest Oncology Group study J. Interferon Res. 10:1990;531-534.
37. Upham J.W., Musk A.W., van-Hagel G.et al. Interferon alpha and doxorubicin in malignant mesothelioma. a phase II study Aust NZ J. Med. 23:1993;683-687.
38. Pogrebniak H., Kranda K., Steinberg S.et al. Cisplatin, α-interferon, and tamoxifen (CIT) for malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 12:1993;398.
39. Tansan S., Emri S., Selcuk T.et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin and alpha-interferon. Oncology. 51:1994;348-351.
40. Pass H.W., Temeck B.K., Kranda K.et al. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann. Surg. Oncol. 2:1995;214-220.
41. Ilson D.H., Saltz L., Martin L.et al. A phase II trial of interferon alpha 2a (IFNα) and carboplatin in malignant mesothelioma. Proc. Am. Soc. Clin. Oncol. 15:1996;456.
42. Metintas M., Özdemir N., Uçgun I.et al. Cisplatin, mitomycin, and α-interferon 2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest. 116:1999;391-398.
43. Vogelzang N.J., Herndon J., Clamon G.H.et al. Paclitaxel (Taxol) for malignant mesothelioma (MM). a phase II study of the Cancer and Leukemia Group B (CALGB 9234) Proc. Am. Soc. Clin. Oncol. 13:1994;405.
44. Sahmoud T., Curran D., Therasse J.et al. Prognostic factors in patients with pleural mesothelioma, the EORTC phase II experience. Proc. Am. Soc. Clin. Oncol. 15:1996;454.
45. Jackman A.L., Calvert A.H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol. 6:1995;871-881.
46. Solheim O.P., Saeter G., Finnanger A.M.et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. a phase II study Br. J. Cancer. 65:1992;956-960.
47. Belani C.P., Herndon J., Vogelzang N.J.et al. Edatrexate for malignant mesothelioma. a phase II study of the Cancer and Leukemia Group B, 9131 Proc. Am. Soc. Clin. Oncol. 13:1994;329.
48. Belani C.P., Herndon J., Vogelzang N.J.et al. Edatrexate with oral leucovorin rescue for malignant mesothelioma. a phase II study of the Cancer and Leukemia Group B 9131 Proc. Am. Soc. Clin. Oncol. 14:1995;352.
49. Vogelzang N.J., Weissman L.B., Herdndon J.E.et al. Trimetrexate in malignant mesothelioma. a CALGB phase II study J. Clin. Oncol. 12:1994;1436-1442.
50. Vogelzang N.J., Herndon J.E., Cirrincione C.et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer. 79:1997;2237-2242.
51. Samuels B.L., Herndon J.E., Harmon D.C.et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma. A phase II study by the Cancer and Leukemia Group B. Cancer. 82:1998;1578-1584.
52. Thödtmann R., Depenbrock H., Blatter J.et al. Preliminary results of a phase 1 study with MTA (LY231514) in combination with cisplatin in patients with solid tumors. Semin. Oncol. 26(Suppl. 6):1999;89-93.
53. Millard F.E., Herndon J., Vogelzang M.R.et al. Gemcitabine for malignant mesothelioma. a phase II study of the Cancer and Leukemia Group B (CALGB 9530) Proc. Am. Soc. Clin. Oncol. 16:1997;475a.
54. Van Meerbeeck J.P., Baas P., Debruyne C.et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer. 85:1999;2577-2582.
55. Bischoff H.G., Manegold C., Knopp M.et al. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol. 17:1998;464a.
56. Byrne M.J., Davidson J.A., Musk A.W.et al. Cisplatin and gemcitabine treatment for malignant mesothelioma. a phase II study J. Clin. Oncol. 17:1999;25-30.
57. Rixe O., Ortuzar W., Alvarez M.et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin. spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel Biochem. Pharmacol. 52:1996;1855-1865.
58. Raymond E., Chaney S.G., Taamma A., Cvitkovic E. Oxaliplatin. a review of preclinical and clinical studies Ann. Oncol. 9:1998;1053-1071.
59. Fink D., Nebel S., Aebi S.et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56:1996;4881-4886.
60. Fink D., Zheng H., Nebel S.et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 57:1997;1841-1845.
61. Raymond E., Buquet-Fagot C., Djelloul C.J.et al. Oxaliplatin (LOHP) and cisplatin (CDDP) in combination with 5-FU, specific thymidase synthase (TS) inhibitors (AG337, ZD1694) and topoisomerase I (Topo-I) inhibitors (SN38, CPT-11), in human colonic, ovarian and breast cancers. Proc. Am. Assoc. Cancer Res. 37:1996;291.
62. Seitz J.F., Douillard J.Y., Paillot B.et al. "Tomudex" (Raltitrexed) plus oxaliplatin as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients. a promising combination Proc. Am. Soc. Clin. Oncol. 18:1999;257a.